I have owned this before, and wanted to hold because I believe the HH antagonist with DNA will be successful in BCC. I know they also have two other early drugs.

However, the royalty rate is only 5-9% with DNA.

So even if it generates a Billion in sale, cris only gets 50-90M

That justifies a 350-400M market cap. So even with blowout success, CRIS is only a 2-3 bagger. At leats that was my line of thinking...any opposing views?